...
首页> 外文期刊>Archives of dermatological research. >Characterization and survival of patients with metastatic basal cell carcinoma in the Department of Veterans Affairs: a retrospective electronic health record review
【24h】

Characterization and survival of patients with metastatic basal cell carcinoma in the Department of Veterans Affairs: a retrospective electronic health record review

机译:退伍军人事务部转移基础细胞癌患者的特征及存活:回顾性电子健康记录审查

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Available descriptive statistics for patients with metastatic basal cell carcinoma (mBCC) are limited. To describe disease characteristics, treatment patterns, survival outcomes, and prognostic factors of patients with mBCC, we conducted a retrospective review of electronic health records in the Department of Veterans Affairs (VA). The primary outcome was survival. Data were also collected on demographics, comorbidities, medications, and procedures. Median (IQR) age of patients with mBCC (n = 475) was 72.0 (17.0) years; 97.9% of patients were male. Almost two-thirds of patients received no initial therapy for mBCC. Median overall survival was 40.5 months [95% CI (confidence interval) 4.8-140.0], and was shorter in patients with distant metastases (17.1 months; 95% CI 2.8-58.0) than in those with regional metastases (59.4 months; 95% CI 17.6-140.0). Because the VA mBCC population is largely male and elderly, the generalizability of these results in other populations is limited and must be interpreted cautiously. Data from this large cohort add valuable information on a rare and poorly researched disease and refine previously wide estimates of overall survival for mBCC.
机译:可用于转移性基础细胞癌(MBCC)的患者的可用描述性统计有限。为了描述MBCC患者的疾病特征,治疗模式,存活结果和预后因素,我们对退伍军人事务部(VA)的电子健康记录进行了回顾性审查。主要结果是生存。还在人口统计数据,组合,药物和程序上收集数据。 MBCC(N = 475)患者的中位数(IQR)年龄为72.0(17.0)岁; 97.9%的患者是男性。几乎三分之二的患者因MBCC接受初始治疗。中位数总生存率为40.5个月[95%CI(置信区间)4.8-140.0],远处转移患者(17.1个月; 95%CI 2.8-58.0)较短,而不是区域转移(59.4个月; 95%) CI 17.6-140.0)。因为VA MBCC人口在很大程度上是男性和老年人,所以这些人群的普遍性是有限的,必须谨慎地解释。来自这一大型队列的数据增加了有关罕见的疾病和较差的疾病的有价值的信息,并细化了MBCC的全面存活率的预先估计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号